Search research articles
Contact Us
Filters
Showing results (401-410 of 417) with videos related to
Page
of 42
Sort By:
Oncotarget
|
March 12, 2015
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries
Zijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries
Chi Young Ok, Ling Li, Zijun Y Xu-Monette, et al.
Leukemia
|
August 30, 2016
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
Y Xia, Z Y Xu-Monette, A Tzankov, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Zijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Zijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 10, 2023
Corrigendum to "Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship." [Modern Pathology 34 (2021) 2154-2167]
L Jeffrey Medeiros, Mario L Marques-Piubelli, Valentina F I Sangiorgio, et al.
Neoplasia (New York, N.Y.)
|
May 8, 2018
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
Xiaoxiao Wang, Xin Cao, Ruifang Sun, et al.
Blood
|
January 25, 2013
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
Shimin Hu, Zijun Y Xu-Monette, Aarthi Balasubramanyam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 6, 2021
Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship
L Jeffrey Medeiros, Mario L Marques-Piubelli, Valentina F I Sangiorgio, et al.
Blood
|
March 2, 2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu, Zijun Y Xu-Monette, Alexander Tzankov, et al.
Page
of 42
Search research articles
Search
Showing results (401-410 of 417) with videos related to
Sort By:
Page
of 42
Oncotarget
|
March 12, 2015
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries
Zijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries
Chi Young Ok, Ling Li, Zijun Y Xu-Monette, et al.
Leukemia
|
August 30, 2016
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
Y Xia, Z Y Xu-Monette, A Tzankov, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Zijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Zijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 10, 2023
Corrigendum to "Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship." [Modern Pathology 34 (2021) 2154-2167]
L Jeffrey Medeiros, Mario L Marques-Piubelli, Valentina F I Sangiorgio, et al.
Neoplasia (New York, N.Y.)
|
May 8, 2018
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
Xiaoxiao Wang, Xin Cao, Ruifang Sun, et al.
Blood
|
January 25, 2013
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
Shimin Hu, Zijun Y Xu-Monette, Aarthi Balasubramanyam, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 6, 2021
Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship
L Jeffrey Medeiros, Mario L Marques-Piubelli, Valentina F I Sangiorgio, et al.
Blood
|
March 2, 2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu, Zijun Y Xu-Monette, Alexander Tzankov, et al.
Page
of 42